The adjustment in price target by Wedbush reflects a slight positive sentiment towards Biogen's stock, yet the maintenance of a Neutral rating suggests that the analyst sees limited upside or downside potential in the short term. This could lead to a neutral impact on the stock price as the market digests this information.